非小细胞肺癌立体定向放疗所致放射性肺炎相关因素研究进展

doi:10.3760/cma.j.cn113030-20200531-00287

Abstract
Figure/Table
References(53)
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Guide

Abstract Stereotactic body radiotherapy (SBRT/SABR) has become an important option in the treatment of early non-small-cell lung cancer (NSCLC). Radiation pneumonitis (RP) is the main side effect of early NSCLC patients after SBRT/SABR. Patient factors, tumor factors and treatment factors are all associated with the occurrence of RP in early NSCLC patients after SBRT/SABR. In recent years, relevant studies have further clarified the relationship between these factors and RP. In addition, the prediction factors related to RP occurrence are further discussed. In this paper, relevant research progresses in recent years were reviewed.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Fu Shoupeng
	Zhang Yingjie
	Li Jianbin

Key words： Radiation pneumonitis Risk factor Carcinoma, non-small-cell lung/stereotactic body radiotherapy

Received: 31 May 2020

ZTFLH:

Fund:Youth Fund of National Natural Science Foundation of China (81201735);Shandong Province Key Research and Development Project (2015GSF118011)

Corresponding Authors: Zhang Yingjie, Email:761094890@qq.com

Cite this article:

Fu Shoupeng,Zhang Yingjie,Li Jianbin. Research progress on risk factors of radiation pneumonitis caused by stereotactic body radiotherapy for non-small-cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2021, 30(12): 1330-1334.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20200531-00287 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2021/V30/I12/1330

[1] Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase Ⅱ trial of medically inoperable stage Ⅰ non-small-cell lung cancer patients treated with stereotactic body radiotherapy[J]. J Clin Oncol, 2009, 27(20):3290-3296. DOI:10.1200/JCO.2008.21.5681.
[2] Timmerman RD, Paulus R, Pass HI, et al. Stereotactic body radiation therapy for operable early-stage lung cancer:findings from the NRG Oncology RTOG 0618 Trial[J]. JAMA Oncol, 2018, 4(9):1263-1266. DOI:10.1001/jamaoncol.2018.1251.
[3] Shi S, Zeng Z, Ye L, et al. Risk factors associated with symptomatic radiation pneumonitis after stereotactic body radiation therapy for stage Ⅰ non-small cell lung cancer[J]. Technol Cancer Res Treat, 2017, 16(3):316-320. DOI:10.1177/1533034616 661665.
[4] Tian S, Switchenko JM, Cassidy RJ, et al. Predictors of pneumonitis-free survival following lung stereotactic body radiation therapy[J]. Transl Lung Cancer Res, 2019, 8(1):15-23. DOI:10.21037/tlcr.2018.10.11.
[5] Kim K, Lee J, Cho Y, et al. Predictive factors of symptomatic radiation pneumonitis in primary and metastatic lung tumors treated with stereotactic ablative body radiotherapy[J]. Radiat Oncol J, 2017, 35(2):163-171. DOI:10.3857/roj.2017.00066.
[6] Alite F, Balasubramanian N, Adams W, et al. Decreased risk of radiation pneumonitis with coincident concurrent use of angiotensin-converting enzyme inhibitors in patients receiving lung stereotactic body radiation therapy[J]. Am J Clin Oncol, 2018, 41(6):576-580. DOI:10.1097/COC.0000000000000324.
[7] Trovo M, Linda A, El Naqa I, et al. Early and late lung radiographic injury following stereotactic body radiation therapy (SBRT)[J]. Lung Cancer, 2010, 69(1):77-85. DOI:10.1016/j.lungcan.2009.09.006.
[8] Stauder MC, Macdonald OK, Olivier KR, et al. Early pulmonary toxicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions[J]. Radiother Oncol, 2011, 99(2):166-171. DOI:10.1016/j.radonc.2011.04.002.
[9] Matsuo Y, Shibuya K, Nakamura M, et al. Dose-volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer[J]. Int J Radiat Oncol Biol Phys, 2012, 83(4):e545-549. DOI:10.1016/j.ijrobp.2012.01.018.
[10] Shinde A, Li R, Kim J, et al. Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly[J]. Semin Oncol, 2018, 45(4):210-219. DOI:10.1053/j.seminoncol.2018.06.002.
[11] Mancini BR, Park HS, Harder EM, et al. Elderly patients undergoing SBRT for inoperable early-stage NSCLC achieve similar outcomes to younger patients[J]. Lung Cancer, 2016, 97:22-27. DOI:10.1016/j.lungcan.2016.04.011.
[12] Cassidy RJ, Patel PR, Zhang X, et al. Stereotactic body radiotherapy for early-stage non-small-cell Lung cancer in patients 80 years and older:a multi-center analysis[J]. Clin Lung Cancer, 2017, 18(5):551-558.e6. DOI:10.1016/j.cllc.2017.03.006.
[13] Hayashi S, Tanaka H, Kajiura Y, et al. Stereotactic body radiotherapy for very elderly patients (age, greater than or equal to 85 years) with stage Ⅰ non-small cell lung cancer[J]. Radiat Oncol, 2014, 9:138. DOI:10.1186/1748-717X-9-138.
[14] Yamamoto T, Kadoya N, Sato Y, et al. Prognostic value of radiation pneumonitis after stereotactic body radiotherapy:effect of pulmonary emphysema quantitated usingg ct images[J]. Clin Lung Cancer, 2018, 19(1):e85-e90. DOI:10.1016/j.cllc.2017.05.022.
[15] Nakamura M, Nishimura H, Nakayama M, et al. Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer[J]. Br J Radiol, 2016, 89(1068):20160560. DOI:10.1259/bjr.20160560.
[16] Glick D, Lyen S, Kandel S, et al. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival in patients treated with lung stereotactic body radiation therapy (SBRT)[J]. Clin Lung Cancer, 2018, 19(2):e219-226. DOI:10.1016/j.cllc.2017.06.021.
[17] Ueki N, Matsuo Y, Togashi Y, et al. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer[J]. J Thorac Oncol, 2015, 10(1):116-125. DOI:10.1097/JTO.0000000000000359.
[18] Onishi H, Marino K, Yamashita H, et al. Case series of 23 patients who developed fatal radiation pneumonitis after stereotactic body radiotherapy for lung cancer[J]. Technol Cancer Res Treat, 2018, 17:1533033818801323. DOI:10.1177/15330338188013 23.
[19] Bahig H, Filion E, Vu T, et al. Severe radiation pneumonitis after lung stereotactic ablative radiation therapy in patients with interstitial lung disease[J]. Pract Radiat Oncol, 2016, 6(5):367-374. DOI:10.1016/j.prro.2016.01.009.
[20] Yoshitake T, Shioyama Y, Asai K, et al. Impact of interstitial changes on radiation pneumonitis after stereotactic body radiation therapy for lung cancer[J]. Anticancer Res, 2015, 35(9):4909-4913.
[21] Ergen SA, Dincbas FO, Yücel B, et al. Risk factors of radiation pneumonitis in patients with NSCLC treated with concomitant chemoradiotherapy—are we underestimating diabetes?—Turkish oncology group (TOG)/lung cancer study group[J]. Clin Respir J, 2020, 14(9):871-879. DOI:10.1111/crj.13220.
[22] Kalman NS, Hugo GD, Mahon RN, et al. Diabetes mellitus and radiation induced lung injury after thoracic stereotactic body radiotherapy[J]. Radiother Oncol, 2018, 129(2):270-276. DOI:10.1016/j.radonc.2018.08.024.
[23] Tekatli H, van't Hof S, Nossent EJ, et al. Use of stereotactic ablative radiotherapy (SABR) in non-small cell lung cancer measuring more than 5cm[J]. J Thorac Oncol, 2017, 12(6):974-982. DOI:10.1016/j.jtho.2017.02.021.
[24] Baba F, Shibamoto Y, Ogino H, et al. Clinical outcomes of stereotactic body radiotherapy for stage Ⅰ non-small cell lung cancer using different doses depending on tumor size[J]. Radiat Oncol, 2010, 5:81. DOI:10.1186/1748-717X-5-81.
[25] Allibhai Z, Taremi M, Bezjak A, et al. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2013, 87(5):1064-1070. DOI:10.1016/j.ijrobp.2013.08.020.
[26] Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. A Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma:four-year results of a prospective phase Ⅱ study[J]. Int J Radiat Oncol Biol Phys, 2009, 75(3):677-682. DOI:10.1016/j.ijrobp.2008.11.042.
[27] Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase Ⅱ study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer[J]. J Clin Oncol, 2006, 24(30):4833-4839. DOI:10.1200/JCO.2006.07.5937.
[28] Chaudhuri AA, Tang C, Binkley MS, et al. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors[J]. Lung Cancer, 2015, 89(1):50-56. DOI:10.1016/j.lungcan.2015.04.014.
[29] Korzets Ceder Y, Fenig E, Popvtzer A, et al. Stereotactic body radiotherapy for central lung tumors, yes we can![J]. Radiat Oncol, 2018, 13(1):77. DOI:10.1186/s13014-018-1017-y.
[30] Aoki S, Yamashita H, Haga A, et al. Stereotactic body radiotherapy for centrally-located lung tumors with 56Gy in seven fractions:A retrospective study[J]. Oncol Lett, 2018, 16(4):4498-4506. DOI:10.3892/ol.2018.9188.
[31] Inoue T, Katoh N, Onimaru R, et al. Stereotactic body radiotherapy using gated radiotherapy with real-time tumor-tracking for stage Ⅰ non-small cell lung cancer[J]. Radiat Oncol, 2013, 8:69. DOI:10.1186/1748-717X-8-69.
[32] Prezzano KM, Ma SJ, Hermann GM, et al. Stereotactic body radiation therapy for non-small cell lung cancer:A review[J]. World J Clin Oncol. 2019,10(1):14-27. DOI:10.5306/wjco.v10.i1.14.1.
[33] Singh AK, Gomez-Suescun JA, Stephans KL, et al. One versus three fractions of stereotactic body radiation therapy for peripheral stage Ⅰ to Ⅱ non-small cell lung cancer:a randomized, multi-institution, phase 2 trial[J]. Int J Radiat Oncol Biol Phys, 2019, 105(4):752-759. DOI:10.1016/j.ijrobp.2019.08.019.
[34] Cummings MA, Ma SJ, Hermann G, et al.comparison of single-and five-fraction regimens of stereotactic body radiation therapy for peripheral early-stage non-small-cell lung cancer:a two-institution propensity-matched analysis[J]. Clin Lung Cancer, 2018, 19(6):511-517. DOI:10.1016/j.cllc.2018.07.006.
[35] Stephans KL, Woody NM, Reddy CA, et al. Tumor control and toxicity for common stereotactic body radiation therapy dose-fractionation regimens in stage Ⅰ non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys. 2018, 100(2):462-469. DOI:10.1016/j.ijrobp.2017.10.037.
[36] Chapman CH, McGuinness C, Gottschalk AR, et al. Influence of respiratory motion management technique on radiation pneumonitis risk with robotic stereotactic body radiation therapy[J]. J Appl Clin Med Phys, 2018, 19(4):48-57. DOI:10.1002/acm2.12338.
[37] Hendriks L, Menis J, De Ruysscher D, et al.combination of immunotherapy and radiotherapy-the next magic step in the management of lung cancer?[J]. J Thorac Oncol, 2020, 15(2):166-169. DOI:10.1016/j.jtho.2019.12.106.
[38] Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell Lung cancer[J]. N Engl J Med, 2017, 377(20):1919-1929. DOI:10.1056/NEJMoa1709937.
[39] Tian S, Switchenko JM, Buchwald ZS, et al. Lung stereotactic body radiation therapy and concurrent immunotherapy:a multicenter safety and toxicity analysis[J]. Int J Radiat Oncol Biol Phys, 2020, 108(1):304-313. DOI:10.1016/j.ijrobp.2019.12.030.
[40] Mohamad O, Diaz de Leon A, Schroeder S, et al. Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy[J]. Oncoimmunology, 2018, 7(7):e1440168. DOI:10.1080/2162402X.2018.1440168.
[41] Verma V, Cushman TR, Selek U, et al. Safety of combined immunotherapy and thoracic radiation therapy:analysis of 3single-institutional phase Ⅰ/Ⅱ trials[J]. Int J Radiat Oncol Biol Phys, 2018, 101(5):1141-1148. DOI:10.1016/j.ijrobp.2018.04.054.
[42] Ding PN, Lord SJ, Gebski V, et al. Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors:a meta-analysis of clinical trials of Gefitinib, Erlotinib, and Afatinib in advanced EGFR-mutated non-small cell lung cancer[J]. J Thorac Oncol, 2017, 12(4):633-643. DOI:10.1016/j.jtho.2016.11.2236.
[43] Zheng L, Wang Y, Xu Z, et al. Concurrent EGFR-TKI and thoracic radiotherapy as first-line treatment for stage ⅠV non-small cell lung cancer harboring EGFR active mutations[J]. Oncologist, 2019, 24(8):1031-e612. DOI:10.1634/theoncologist.2019-0285.
[44] Basler L, Kroeze SG, Guckenberger M. SBRT for oligoprogressive oncogene addicted NSCLC[J]. Lung Cancer, 2017, 106:50-57. DOI:10.1016/j.lungcan.2017.02.007.
[45] Wang Z, Zhu XX, Wu XH, et al. Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer[J]. Am J Clin Oncol, 2014, 37(2):148-153. DOI:10.1097/COC.0b013e31826e071b.
[46] Parker SM, Siochi RA, Wen S, et al. Impact of tumor size on local control and pneumonitis after stereotactic body radiation therapy for lung tumors[J]. Pract Radiat Oncol, 2019, 9(1):e90-e97. DOI:10.1016/j.prro.2018.09.003.
[47] Ueyama T, Arimura T, Takumi K, et al. Risk factors for radiation pneumonitis after stereotactic radiation therapy for lung tumours:clinical usefulness of the planning target volume to total lung volume ratio[J]. Br J Radiol, 2018, 91(1086):20170453. DOI:10.1259/bjr.20170453.
[48] Chaudhuri AA, Binkley MS, Rigdon J, et al. Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following stereotactic ablative radiotherapy (SABR)[J]. Radiother Oncol, 2016, 119(3):454-460. DOI:10.1016/j.radonc.2016.05.007.
[49] Harder EM, Park HS, Chen ZJ, et al. Pulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy[J]. Pract Radiat Oncol, 2016, 6(6):e353-359. DOI:10.1016/j.prro.2016.01.015.
[50] Barriger RB, Forquer JA, Brabham JG, et al. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2012, 82(1):457-462. DOI:10.1016/j.ijrobp.2010.08.056.
[51] Chang JY, Liu H, Balter P, et al. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage Ⅰ non-small cell lung cancer[J]. Radiat Oncol, 2012, 7:152. DOI:10.1186/1748-717X-7-152.
[52] Guo L, Ding G, Xu W, et al. Prognostic biological factors of radiation pneumonitis after stereotactic body radiation therapy combined with pulmonary perfusion imaging[J]. Exp Ther Med, 2019, 17(1):244-250. DOI:10.3892/etm.2018.6936.
[53] Moré JM, Eclov NC, Chung MP, et al. Feasibility and potential utility of multicomponent exhaled breath analysis for predicting development of radiation pneumonitis after stereotactic ablative radiotherapy[J]. J Thorac Oncol, 2014, 9(7):957-964. DOI:10.1097/JTO.0000000000000182.